Oral Semaglutide: Diabesity Business As Usual Is Doomed
February 23, 2018 — Wachet auf! As if the clues were not already present, an announcement yesterday makes it plain. Competitors in the sleepy diabesity market had best wake up. The first ever oral GLP-1 agonist for diabetes and obesity – semaglutide – is looking good in clinical trials. That means everyone else had better get serious about innovation. Or risk becoming […]